| Objective:To study the mechanism of epidermal growth factor receptor kinase substrate 8-like protein 3(EPS8L3)in hepatocellular carcinoma(HCC)and to screen new target for systemic therapy of HCC in the advanced stage.Methods:Genes with up-regulated expression in tumor tissue compared with those in normal tissue were obtained in accordance with the bioinformatic analysis of RNA-seq data of HCC in the Cancer Genome Atlas(TCGA)database.Furthermore,using short hairpin RNA(shRNA)to knockdown the expression of the target gene,the effect of target gene expression knockdown was analyzed on the proliferation,apoptosis,invasion and migration of HCC cells.In addition,after knockdown of the target gene,sorafenib at different doses were used jointly in the treatment of HCC cells to observe the therapeutic effect and further verify the clinical value of corresponding results.Results:The differentially expressed genes were analyzed in normal liver and HCC tissues through data analysis from TCGA database,and a gene with unknown function was found eventually,which was EPS8L3.The mRNA and protein expression levels of EPS8L3 were significantly up-regulated in HCC tissues,which were positively correlated with the poor prognosis of HCC.The results of comparative analysis between HCC cells with and without the knockdown of EPS8L3 indicated that EPS8L3 gene was related to the division,proliferation and apoptosis of HCC cells.Furthermore,in vitro cell experiment verified that knockdown of EPS8L3 could inhibit the proliferation and invasion,and promote the apoptosis of HCC cells.Meanwhile,EPS8L3 knockdown could improve the effect of sorafenib on HCC at the cellular level.Conclusion:EPS8L3 can promote the proliferation,invasion and migration,and inhibit the apoptosis of HCC cells,which is strongly associated with the poor prognosis of HCC.Furthermore,knockdown of EPS8L3 at the genetic level can significantly inhibit the proliferation,invasion and migration of HCC cells.In addition,knockdown of EPS8L3 increases the sensitivity of sorafenib in the treatment of HCC.Objective:To analyze the risk factors of recurrence in patients with BCLC 0-A hepatocellular carcinomaafter surgical treatment.Methods:We retrospectively investigated 218 patients who had undergone surgical resection because of BCLC 0-A hepatocellular carcinoma.Fifteen clinicopathologic factors possibly influencing the recurrence and survival were selected,and multivariate analysis of these parameters was performed using the Cox proportional hazards model.Survival analysis was done using the Kaplan-Meier method.Results:The overall 1-,3-,5-year survival rates of 218 patients were 95.9%、85.3%and 67.6%,respectively.Median survival from time of primary resection was 35 months.The total 1-,3-and 5-year disease-free survival rate(DFS)was 84.4%,56.5%and 47.0%,respectively.The median time to recurrence was 25 months.Univariate analysis showed that positive AFP,tumor diameter,satellite nodules,involvement of hepatic capsule,tumor differentiation,microvascular invasion and BCLC stagingsignificantly affect the postoperative survival.The Cox multivariate analysis indicated that involvement of hepatic capsule,positive AFP,tumor differentiation are independent prognostic factors.Univariate analysis showed that cirrhosis,positive AFP,satellite nodules,involvement of hepatic capsule,tumor differentiation,microvascular invasion associated with recurrence,Cox multivariate analysis showed that satellite nodules,involvement of hepatic capsule,microvascular invasion were the independent risk factors influencing the recurrence.Conclusions:Surgical resection is the first choice for BCLC 0-A hepatocellular carcinoma.Cox multivariate analysis showed that satellite nodules,involvement of hepatic capsule,microvascular invasion were the independent risk factors influencing the recurrence.Postoperative TACE do not benefit patients in survival with risk factors of recurrence. |
PDF Full Text Request